REDUCING MYELIN-MEDIATED INHIBITION OF AXON REGENERATION

摘要

Oligodendrocyte−myelin glycoprotein (OMgp)−specific binding agents are used to reduce OMgp−mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.